Search Results
You are looking at 1 - 1 of 1 items for
- Author: Katherine N Balantekin x
- Refine by access: All content x
Center for Ingestive Behavior Research, University at Buffalo, Buffalo, New York, USA
Search for other papers by Katherine N Balantekin in
Google Scholar
PubMed
Search for other papers by Martin J Kretz in
Google Scholar
PubMed
Center for Ingestive Behavior Research, University at Buffalo, Buffalo, New York, USA
Search for other papers by Elizabeth G Mietlicki-Baase in
Google Scholar
PubMed
Binge eating is a central component of two clinical eating disorders: binge eating disorder and bulimia nervosa. However, the large treatment gap highlights the need to identify other strategies to decrease binge eating. Novel pharmacotherapies may be one such approach. Glucagon-like peptide-1 (GLP-1) is an intestinal and brain-derived neuroendocrine signal with a critical role in promoting glycemic control through its incretin effect. Additionally, the energy balance effects of GLP-1 are well-established; activation of the GLP-1 receptor (GLP-1R) reduces food intake and body weight. Aligned with these beneficial metabolic effects, there are GLP-1R agonists that are currently used for the treatment of diabetes and obesity. A growing body of literature suggests that GLP-1 may also play an important role in binge eating. Dysregulation of the endogenous GLP-1 system is associated with binge eating in non-human animal models, and GLP-1R agonists may be a promising approach to suppress the overconsumption that occurs during binge eating. Here, we briefly discuss the role of GLP-1 in normal energy intake and reward and then review the emerging evidence suggesting that disruptions to GLP-1 signaling are associated with binge eating. We also consider the potential utility of GLP-1-based pharmacotherapies for reducing binge eating behavior.
